Fifth Amendment to Credit Agreement between Staar Surgical Company and Wells Fargo Bank
Contract Categories:
Business Finance
›
Credit Agreements
Summary
This amendment updates the existing credit agreement between Staar Surgical Company and Wells Fargo Bank. It extends the maturity date of the credit facility, introduces a 0.25% annual commitment fee on unused credit, and adds new financial reporting and disclosure requirements for Staar. The amendment also allows the bank to conduct appraisals and access company records. These changes are effective as of October 1, 2001, and are subject to the conditions outlined in the amendment.
EX-10.71 10 dex1071.txt FIFTH AMENDMENT TO CREDIT AGREEMENT October 1, 2001 Staar Surgical Company 1911 Walker Avenue Monrovia, California 91016 Attention: David Bailey Chief Executive Officer Re: Fifth Amendment to Credit Agreement Ladies and Gentlemen: We refer to (a) the letter agreement dated as of October 31, 2000, as amended by the letter amendment dated December 22, 2000, the letter amendment dated April 1, 2001 and two letter amendments dated July 1, 2001 (said letter agreement, as so amended, herein called the "Credit Agreement"), between Staar ---------------- Surgical Company, a Delaware corporation (the "Borrower"), and Wells Fargo Bank, -------- National Association, a national banking association (the "Bank"), and (b) the ---- Revolving Line of Credit Note dated October 31, 2000, as amended by the letter amendment dated April 1, 2001 referred to above by and one of the letter amendments dated July 1, 2001 referred to above (said Note, as so amended, herein called the "Line of Credit Note"), in the amount of $7,000,000 made by ------------------- the Borrower in favor of the Bank. Terms defined in the Credit Agreement and not otherwise defined herein have the same respective meanings when used herein. 1. Amendments to Credit Agreement. Effective as of the date of this letter ------------------------------ amendment but subject to satisfaction of the terms and conditions specified herein, the Credit Agreement is hereby amended as set forth below. (a) The first sentence of the second paragraph of the Credit Agreement is amended by deleting the date "April 1, 2001" and substituting the date "January 4, 2002." follows: (b) A new paragraph II.5 is added to the Credit Agreement to read as follows: "5. Commitment Fee. Borrower will pay Bank a commitment fee at the -------------- rate of 0.25% per annum (computed on the basis of a 360-day year and actual --- ----- days elapsed) on the average daily unused portion of the Line of Credit; from October 1, 2001 until the maturity date of the Line of Credit, payable monthly in arrears on the first business day of each calendar month, Staar Surgical Company October 1, 2001 Page 2 commencing on November 1, 2001, and on the maturity date of the Line of Credit." (c) Paragraph III.4 of the Credit Agreement is amended by deleting the words "the date hereof ' and substituting the date "October 1, 2001." (d) Paragraph III.5 of the Credit Agreement is amended by (i) deleting the date "June 30, 2000" and substituting the date "June 30, 2001" and (ii) deleting the words "prior to the date hereof." (e) Part III of the Credit Agreement is amended by adding new paragraphs III.12 and III.13 to read as follows: "12. Patents. No patent has been issued in the United States to or for ------- the benefit of, and no patent application has been filed in the United States by or on behalf of, Borrower or any subsidiary thereof, except as listed in Schedule 1 attached hereto or as otherwise disclosed to Bank in writing from time to time. 13. Credit Facilities. Since September 30, 2001, no credit facility ----------------- has been available to Borrower or any subsidiary thereof except for (a) the credit facility made available to Borrower by Bank pursuant to this letter, (b) the credit facility or facilities made available to Borrower and/or one or more subsidiaries thereof, the principal terms of which are described in Schedule 2 attached hereto, and (c) such other credit facilities (including the principal terms thereof) as disclosed by Borrower to Bank in writing from time to time." (f) Paragraph V.3 of the Credit Agreement is amended by deleting the word "and" at the end of paragraph V.3(c), deleting paragraph V.3(e) and adding the following after paragraph V.3(d): "(e) within 30 days after the end of each calendar month, commencing with September of 2001, unaudited consolidated and consolidating balance sheets of Borrower as of the end of such month and unaudited consolidated and consolidating statements of income and cash flows of Borrower for the period commencing at the end of the preceding fiscal year and ending with the end of such month, all in form, scope and detail satisfactory to Bank and duly certified (subject to normal-year end audit adjustments and the absence of footnotes) by the chief financial officer or chief accounting officer of Borrower as having been prepared in accordance with generally accepted accounting principles; Staar Surgical Company October 1, 2001 Page 3 (f) not later than the third Friday of each calendar month, (i) commencing on October 19, 2001, a projection of the consolidated cash flow of Borrower, detailing cash receipts and cash disbursements, for the 13-week period commencing on such Friday and (ii) commencing on November 16, 2001, a comparison of Borrower's actual consolidated cash flow to the projection of such cash flow, together with a written explanation of any variance exceeding 15%, in each case in form, scope and detail satisfactory to Bank and duly certified by an officer of Borrower, and in a manner, acceptable to Bank; (g) not later than the last business day of each calendar month, commencing on October 31, 2001, an aged listing of the United States domestic accounts receivable and United States domestic accounts payable of Borrower and its United States domestic subsidiaries as of the last day of the preceding calendar month, in form, scope and detail satisfactory to Bank and duly certified by an officer of Borrower, and in a manner, acceptable to Bank; (h) not later than 60 days after the end of each fiscal quarter of Borrower, commencing with the fiscal quarter ended on September 30, 2001, a comparison of Borrower's actual consolidated financial performance to the projection of such financial performance contained in the financial projections for various periods in 2001, 2002, 2003 and 2004 first delivered by Borrower to Bank on July 25, 2001, together with a written explanation of any variance exceeding 15%, all in form, scope and detail satisfactory to Bank and duly certified by an officer of Borrower, and in a manner, acceptable to Bank; (i) within 3 days after completion by Brian Testo Associates LLC of its written appraisal of Borrower's inventory and equipment conducted in September of 2001, a copy of such appraisal; and (j) promptly upon request by Bank, such other information concerning the business, condition (financial or otherwise), operations, performance, properties or prospects of Borrower or any subsidiary thereof as Bank may from time to time reasonably request." (g) Part V of the Credit Agreement is amended by adding a new paragraph V.18 to read as follows: "18. Appraisals, Etc. At any reasonable time and from time to time, --------------- upon reasonable prior notice to Borrower, permit Bank and its (or its counsel's) Staar Surgical Company October 1, 2001 Page 4 consultants, agents and representatives to examine and make copies of and abstracts from the records and books of account of, and visit the properties and have access to the assets of, Borrower and its subsidiaries and to discuss the affairs, finances and accounts of Borrower and its subsidiaries with any of their respective officers, directors and employees and with their independent certified public accountants, including for the purpose of conducting (a) an appraisal of the patents, patent applications and related agreements and other documents of Borrower and its subsidiaries and (b) if Bank is not satisfied with the appraisal referred to in paragraph V.3(i) hereof, an appraisal of the inventory and equipment of Borrower and its subsidiaries, all at the sole cost and expense of Borrower." (h) New Schedules 1 and 2 are added to the end of the Credit Agreement in the forms of Schedules 1 and 2, respectively, attached to this letter amendment. 2. Amendments to Line of Credit Note. Effective as of the date of this --------------------------------- letter amendment but subject to satisfaction of the terms and conditions specified herein, the Line of Credit Note is hereby amended as set forth below. (a) The first sentence of paragraph (a) under the caption "Interest" in the Line of Credit Note is amended in full to read as follows: "The outstanding principal balance of this Note shall bear interest (computed on the basis of a 360-day year, actual days elapsed) at a rate per annum equal to the sum of the Prime Rate in effect from time to plus 1.0% per annum." (b) Paragraph (c) under the caption "Interest" in the Line of Credit Note is amended in full to read as follows: "(c) Default Interest. Upon the occurrence and during the - ---------------- continuation of any Event of Default, the outstanding principal balance of this Note shall bear interest until paid in full at an increased rate per annum (computed on the basis of a 360-day year, actual days elapsed) equal to 4% above the rate of interest from time to time otherwise applicable to this Note." (c) The last sentence of paragraph (a) under the caption "Borrowing and Repayment" in the Line of Credit Note is amended by deleting the date "October 1, 2001" and substituting the date "January 4, 2002." Staar Surgical Company October 1, 2001 Page 5 (d) Paragraph (e) under the caption "Events of Default" in the Line of Credit Note is amended by adding the words "or representation made" after the word "provided." 3. Waiver of Events of Default under Credit Agreement. Effective as of the -------------------------------------------------- date of this letter amendment but subject to satisfaction of the terms and conditions specified herein, the Bank hereby waives (a) the Event of Default caused by the Borrower's violation of its covenant contained in paragraph V.9(b) of the Credit Agreement with respect to the Borrower's fiscal quarter ended on June 30, 2001 and (b) the Event of Default expected to be caused by the Borrower's violation of its covenant contained in paragraph V.9(b) of the Credit Agreement with respect to the Borrower's fiscal quarter ended on September 30, 2001. 4. Representations and Warranties. The Borrower hereby represents and ------------------------------ warrants for the benefit of the Bank that (a) the representations and warranties of the Borrower contained in the Loan Documents are correct in all material respects on and as of the date of this letter amendment, before and after giving effect to the same, as if made on and as of such date, and (b) no event has occurred and is continuing, or would result from the effectiveness of this letter amendment, that constitutes an Event of Default. 5. Conditions Precedent. This letter amendment shall become effective as of -------------------- the date first set forth above, subject to the conditions subsequent set forth in paragraph 6 below, when and if, on or before October 5, 2001, (a) the Borrower and the Bank execute counterparts of this letter amendment and deliver them to each other and (b) the Borrower pays the Bank an extension fee of $10,500 (which the Bank is hereby authorized to collect on or after October 1, 2001 by charging the Borrower's account number 4159-251172 (or any other account) with the Bank, in accordance with paragraph II.4 of the Credit Agreement). 6. Conditions Subsequent. The Borrower's delivery to the Bank of the --------------------- documents specified below, in form and substance satisfactory to the Bank and in the number of originals requested thereby, by the respective dates specified below shall be conditions subsequent to the effectiveness of this letter amendment: (a) not later than October 15, 2001, the following: (i) a certificate of the Secretary of the Borrower as to the incumbency, and setting forth a specimen signature, of each person who has signed this letter amendment, or will sign any Loan Document or modification thereof in the future, on behalf of the Borrower; and (ii) a certificate of the Secretary of Borrower certifying that the copy of the resolutions of the Board of Directors of the Borrower attached to such certificate, authorizing the Borrower to enter into, deliver and perform its obligations under this letter amendment, is correct and complete and in full force and effect; and Staar Surgical Company October 1, 2001 Page 6 (b) not later than October 31, 2001, the following: (i) projected consolidated balance sheets of the Borrower as of the quarter-end and year-end dates, through December 31, 2004, of the financial projections for various periods in 2001, 2002, 2003 and 2004 delivered by the Borrower to the Bank on July 25, 2001, such balance sheets to be certified by an officer of the Borrower, and in a manner, acceptable to the Bank; (ii) a copy of (A) each "prepayment letter agreement" or equivalent agreement (including any amendments or waivers with respect thereto) with St. Luke's Cataract and Laser Institute to which the Borrower or any subsidiary thereof is a party and (B) Borrower's standard form of consignment contract, in each case certified by an officer of the Borrower, and in a manner, acceptable to the Bank; (iii) a list of all insurance policies maintained for the Borrower or any subsidiary thereof, together with copies of such policies (including any amendments or waivers with respect thereto), certified by an officer of the Borrower, and in a manner, acceptable to the Bank; (iv) one or more insurance certificates naming the Bank as additional insured and/or loss payee, as the Bank may require, under such of the aforementioned insurance policies as the Bank may require; and (v) a list of all patents issued outside the United States to or for the benefit of, and all patent applications filed outside the United States by or on behalf of, the Borrower or any subsidiary thereof, certified by an officer of the Borrower, and in a manner, acceptable to the Bank 7. Release of Claims. The Borrower represents and warrants to the Bank that ----------------- it has diligently and thoroughly investigated the existence of any Claim (as defined below) and that, to its knowledge and belief, no Claim exists and no facts exist that could give rise to or support a Claim. As additional consideration for the Bank's entering into this letter amendment, the Borrower and each of its agents, employees, directors, officers, attorneys, affiliates, subsidiaries, successors and assigns (each a "Releasing Party") hereby release --------------- and forever discharge the Bank and each of its agents, direct and indirect shareholders, employees, directors, officers, attorneys, branches, affiliates, subsidiaries, successors and assigns (each a "Released Party") from any and all -------------- damages, losses, claims, demands, liabilities, obligations, actions and causes of action whatsoever (collectively "Claims") that the Releasing Parties or any ------ of them may, as of the date hereof, have or claim to have against any or all of the Released Parties, in each case whether currently known or unknown or with respect to which the facts are known (or should have been known), that could give rise to or support a Claim on account of or in any way relating to, arising out of or based upon any Loan Document, any amendment, waiver or other modification with respect thereto, the negotiation or documentation hereof or thereof, any of the transactions contemplated hereby or thereby, or any action or omission in connection with any of the foregoing, including all such damages losses, claims, demands, liabilities, obligations, actions and causes of action heretofore sustained or that may arise as a consequence of the dealings between the parties up to the date hereof in connection with or in any way related to any Loan Document or any amendment, Staar Surgical Company October 1, 2001 Page 7 waiver or other modification with respect thereto. Each Releasing Party further represents and warrants that it has not heretofore assigned, and covenants and agrees that it will not hereafter sue any Released Parry upon, any Claim released or purported to be released under this section. Each Releasing Party will indemnify and hold harmless the Released Parties against any loss or liability on account of any actions brought by any Releasing Party or its assigns or prosecuted on behalf of any Releasing Party and relating to any Claim released or purported to be released under this section. It is further understood and agreed that any and all rights under the provisions of Section 1542 of the California Civil Code are expressly waived by each of the Releasing Parties. Section 1542 of the California Civil Code provides as follows: "A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR." 8. Reference to and Effect on Loan Documents. On and after the effective ----------------------------------------- date of this letter amendment, (a) each reference in the Credit Agreement to "this letter," "hereunder," "hereof," "herein" or words of like import referring to the Credit Agreement, and each reference in the other Loan Documents to "the Agreement," "thereunder," "thereof," "therein" or words of like import referring to the Credit Agreement, shall mean and be a reference to the Credit Agreement as amended by this letter amendment, and (b) each reference in the Line of Credit Note to "this Note," "hereunder," "hereof," "herein" or words of like import referring to the Line of Credit Note, and each reference in the other Loan Documents to "the Line of Credit Note," "thereunder," "thereof," "therein" or words of like import referring to the Line of Credit Note, shall mean and be a reference to the Line of Credit Note as amended by this letter amendment. The Credit Agreement and the Line of Credit Note, as amended by this letter amendment, are and shall continue to be in full force and effect and are hereby ratified and confirmed in all respects. 9. Execution in Counterparts. This letter amendment may be executed in any ------------------------- number of counterparts and by the parties hereto in separate counterparts, each of which counterparts shall be an original and all of which taken together shall constitute one and the same letter amendment. Staar Surgical Company October 1, 2001 Page 8 10. GOVERNING LAW. THIS LETTER AMENDMENT SHALL BE GOVERNED BY, AND ------------- CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF CALIFORNIA WITHOUT REFERENCE TO THE CHOICE-OF-LAW PRINCIPLES THEREOF. Very truly yours, WELLS FARGO BANK, NATIONAL ASS0CIATION By: /s/ EDITH R. LIM ----------------------- Name: EDITH R. LIM Title: Vice President Agreed as of the date first written above: STAAR SURGICAL COMPANY By: /s/ John S Santos ------------------ Name: John S Santos Title: VP CFO SCHEDULE 1 PATENTS AND PATENT APPLICATIONS ------------------------------- To be delivered to Wells Fargo by October 12, 2001 By: /s/ John S. Santos -------------------- STAAR Surgical Co. /s/ Edith R. Lim -------------------- Wells Fargo STAAR SURGICAL COMPANY, INC.
United States Patent[19] [11] Patent Number : 4,573,998 Mazzocco [45] Date Of Patent: Mar. 4, 1986 - -------------------------------------------------------------------------------- [54] METHODS FOR IMPLANTATION OF DEFORMABLE INTRAOCULAR LENSES [75] Inventor: Thomas R. Mazzocco, Granada Hills, Calif. [73] Assignee: Staar Surgical Co., Monrovia, Calif [21] Appl. No.: 346,105 [22] Filed: Feb. 5, 1982 [51] Int. Cl./4/....................... A61F 2/16; A61B 17/00; A61B 17/28 [52] U.S. Cl. ..................................623/6;128/303 R; 128/321 [58] Field of Search ..................... 3/13, 1; 351/160 R, 351/160 H [56] References Cited U.S. PATENT DOCUMENTS 3,034,403 5/1962 Neefe ......................................3/13 X 3,760,045 9/1973 Thiele et al. .............................3/13 X 3,991,426 11/1976 Flom et al. ..................................3/13 3,992,563 11/1976 Tanaka .....................................3/13 X 4,110,848 9/1978 Jensen .......................................3/13 4,131,604 12/1978 Szycher ...................................3/1 A X 4,153,641 5/1979 Deichert et al. .......................351/160 H X 4,172,297 10/1979 Schlegel .....................................3/13 4,206,518 6/1980 Jardon et al. ................................3/13 4,242,291 12/1980 Hughes et al. .........................351/160 H X 4,244,060 1/1981 Hoffer .......................................3/13 4,253,199 3/1981 Banko ........................................3/13 4,285,073 8/1981 Szycher ......................................3/13 4,315,337 2/1982 Choyce ......................................3/13 4,365,360 12/1982 Ong .........................................3/13 4,377,329 3/1983 Poler ......................................3/13 X FOREIGN PATENT DOCUMENTS ###-###-#### 10/1978 Fed. Rep. of Germany ...................3/13 1103399 5/1955 France .................................3/13 Primary Examiner-Ronald L. Frinks Attorney, Agent, or Firm-Frank Frisenda, Jr. [57] ABSTRACT The invention provides an improved intraocular lens structure comprising a deformable optical zone portion with prescribed memory characteristics and methods and devices for implantation of such lens in the eye. The unique optical zone portion of the lens can be deformed by compressing, rolling, folding, stretching, or can be deformed by a combination of these techniques to temporarily reduce the optical zone portion to a diameter of about 80% or less of the cross-sectional diameter of the optical zone portion in an unstressed state. After insertion into the eye, the optical zone portion returns to its original configuration, full size and fixed focal length. The inventive methods and devices for implantation permit insertion of the improved lens through a relatively small incision made in the ocular tissue, thereby providing a safer, more convenient surgical procedure and more comfortable fit for the eye. 24 Claims, 63 Drawing Figures [GRAPHIC] -5- SCHEDULE 2 OTHER CREDIT FACILITIES ----------------------- A. Credit Facility Provided to by --------------------------------------------------------------------------- 1. date commencement of facility: 2. date of termination or maturity of facility: 3. maximum amount available under facility (in U.S.dollars): 4. amount outstanding under facility (in U.S.dollars) as of 9/30/01: 5. interest rate: 6. amortization, if any: 7. name(s) of guarantor(s), if any: 8. collateral, if any: To be delivered to Wells Fargo by October 12, 2001. By: /s/ Illegible ---------------------- STAAR Surgical Co. /s/ Illegible ----------------------- Wells Fargo SCHEDULE 2 ---------- OTHER CREDIT FACILITIES ----------------------- A. Credit Facility Provided to STAAR SURGICAL AG by UBS AG,BERNE - -- ------------------------------------------------------------- 1. date of commencement of facility: November,27,2000 -- -------------------------------------------------- 2. date of termination or maturity of facility: until further notice -- ----------------------------------------------------------------- 3. maximum amount available under facility (in dollars): -- ----------------------------------------------------- a) USD 1,859,543 (CHF 3,000,000) ---------------------------------- b) USD 1,239,695 (CHF 2,000,000) ---------------------------------- 4. amount outstanding under facility (in U.S. dollars) as of 9/30/01: ------------------------------------------------------------------ 5. interest rate: ------------- fixed advance: 4.49% -------------------- fixed advance: 4.73% -------------------- current acct: 5.5%(pa) + 0,25% (per quater) credit commission ------------------------------------------------------------- 6. amortization, if any: --------------------- a) none ------- b)USD 309,924 (CHF 500,000) per annum, payable half-yearly with USD ------------------------------------------------------------------- 154,962 (CHF 250,000) each time on June 30 and December 31; for the ------------------------------------------------------------------- first time on June 30,2002. --------------------------- 7. name(s) of guarantor(s), if any: none -- ------------------------------------- 7. collateral, if any: ------------------- General Purposes Assignment of Claims (Global Assignment) --------------------------------------------------------- SCHEDULE 2 ---------- OTHER CREDIT FACILITIES ----------------------- A. Credit Facility Provided to DOMILENS GmbH by Bankhaus Wolbern & Co. - -- ------------------------------------------------------------------- 1. date of commencement of facility: 01.06.2000 -- -------------------------------------------- 2. date of termination or maturity of facility: -------------------------------------------- from 01.09.2001- 31.10.2001 EURO 1.000.000,-- USD 914.409,-- from 01.11.2001- 30.11.2001 EURO 750.000,-- USD 685.807,-- from 01.12.2001 up to 28.02.2003 the amount reduces monthly by around figure of EURO 50.000,-- USD 45.720,-- 3. maximum amount available under facility (in U.S.dollars): --------------------------------------------------------- 4. amount outstanding under facility (in U.S.dollars) as of 9/30/01: ----------------------------------------------------------------- point 3 and 4: this is just a credit line up to EURO 1,0 Mio we are always using. 5. interest rate: 9% pa -- ------------------------------- 6. amortization, if any: None -- -------------------------- 7. name(s) of guarantor(s), if any: Gunther Roepstorff and -- ---------------------------------------------------------------------- DOMILENS GmbH ------------- 8. collateral, if any: None -- ------------------------